The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC | Common | 00287Y109 | 287,165 | 5,277,800 | SH | SOLE | 5,057,800 | 0 | 220,000 | ||
ALKERMES PLC | SHS | G01767105 | 305,473 | 5,206,633 | SH | SOLE | 5,054,833 | 0 | 151,800 | ||
NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 127,884 | 20,461,392 | SH | SOLE | 19,671,392 | 0 | 790,000 | ||
PROTHENA CORP PLC | SHS | G72800108 | 281,222 | 6,202,525 | SH | SOLE | 5,941,864 | 0 | 260,661 | ||
REYNOLDS AMERICAN INC | Common | 761713106 | 726,351 | 16,407,290 | SH | SOLE | 15,722,472 | 0 | 684,818 | ||
THERAVANCE BIOPHARMA INC | Common | G8807B106 | 3,964 | 360,685 | SH | SOLE | 360,685 | 0 | 0 |